vareniclina
TRANSCRIPT
Vareniclina
Andrea Isabel Arteaga
Action at 42 nicotine receptor
Partial agonist/antagonist Releases lower amounts of dopamine into
brain than smoke• Reduces withdrawal
• Not as addictive as smoke
Blocks nicotine from binding to receptor• Prevents reward of smoking
Mecanismo de acción
Efectos adversos
Nausea Sleep
Disturbance Constipation
Gas Vomiting changes in behavior
Evidencia
Varenicline phase 2 trial
CO-confirmed 4-week continuous quit rates,
at week 12
45.1
50.6
12.4
0
10
20
30
40
50
60
0.5 mg 2/day
1.0 mg 2/day
Placebo
p<0.0001
Varenicline clinical trial
CO-confirmed 4-week continuous quit rates,
at week 7
25.4
40.8
28.6
13.8
31
0
5
10
15
20
25
30
35
40
45
0.3 mg 1/day
1.0 mg 1/day
1.0 mg 2/day
Zyban 150*2
Placebo
p<0.05
Varenicline 12 semaines + si succès encore
12 semaines varenicline ou placebo
50
71
0
10
20
30
40
50
60
70
80
12 sem +
placebo
12+12 sem
Communiqué de presse du 15 nov 2005,
Pfizer
Increased CV risk with smoking cessation
drug varenicline: New meta-analysis
Sources
1. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with
varenicline: a systematic review and meta-analysis. CMAJ 2011. Available at:http://www.cmaj.ca
2. Hays JT. Varenicline for smoking cessation: Is it a heartbreaker? CMAJ 2011.